Results indicated that Atezolizumab/Bevacizumab combination showed improved outcomes with ≥1% PD-L1 expression of tumor-infiltrating immune cells when monitored via immunohistochemistry (Crist and Balar, 2017). The gene discussed is CD274; the disease is neoplasm.